RPL201

RPL201 is a small molecule therapeutic being developed by Riverside Pharmaceuticals for the treatment of spinal muscular atrophy (SMA) and muscular dystrophies, including Duchenne muscular dystrophy (DMD). Described as an off-patent, previously clinical-stage compound, RPL201 has an established safety profile from prior human trials involving over 200 subjects. Its mechanism of action focuses on enhancing skeletal muscle functioning and potentially supporting spinal motor neuron health, although its specific molecular target has not been publicly disclosed. The drug is currently in preclinical development, leveraging its known tolerability to accelerate its path toward clinical application in rare neuromuscular disorders.